Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Topotecan in Recurrent SCLC
NCT00087048Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Apr 2004
- Primary completion
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of topotecan in small cell lung cancer (SCLC), sponsored by Case Comprehensive Cancer Center. Primary endpoint: Overall Survival. Started Apr 2004; status: terminated.
02
Drugs
topotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00087048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00087048.